All those things and more. I genuinely couldn't less about their prospects, I just thought his generalisation was idiotic. If anyone chooses to invest in a company run by dodgy trev and believe that their impractical test will get to market that's their choice. Carl desperately loves bickering with people on twitter, it's all he does - seemingly on a full time basis, which is why I noted that he didn't want to talk about his test and left it. He's previously argued that their comedy test can be used for events, it's beyond idiotic. Leave them to it. If anyone on here is in there (looks like MrA is...), then good luck, time your trades with pump and dump Trev would be your best bet...
RE: The rude poster on Twitter to Carl21 Apr 2021 12:43
Yes, you’re right. Carl should indeed have that attitude, it’s a real shame he was trying to undermine the incredible results from the clinical validation - 100% within the accepted range for infectious individuals and 98% overall.
Carl is moronically gormless and clearly vastly out of touch with the real world. He was trying to suggest that our clinically proven 100% sensitive lateral flow test designed specifically to identify infectious individuals wasn’t sensitive. I just pointed out their comical shoebox will never be commercialised and he decided to retweet it as he didn’t have an answer. He then started prattling about academics as I told him to get a proper job. These things happen, not sure it’s worthy of a thread on here or there. Seems they’re as sensitive as our world beating test.
Unfortunately our study doesn’t match up to PD phase 3a, so I guess we’ll have to sell the best test elsewhere. It’s as simple as that, either the govt want to procure the best (and a sovereign test) to boot or they don’t. Turns out we’ve smashed the equivalent of 3b so they can either ignore the frozen sample step or stick rigidly to the framework. If we don’t fit the DPS I’d expect them to directly order anyway, it’s not like it matters...
It might have added to it, but the fundamentals over there are shot. Future prospects will have been linked to becoming a strategic partner of DHSC and that’s now changed to a future of a court case. The backside has fallen out of their revenue stream and court battles aren’t a good luck for striking new deals. They’ve a rocky road ahead.
Quite a few on here added yesterday, myself included. A bit too early in the day unfortunately, but with market leading sensitivity - 100% in the infectious range - it was impossible not to get a bit trigger happy. I’ve zero concerns that I’ll not soon see that tranche in positive territory.
I noted that yesterday’s RNS only declared sensitivity in the headline. I’m guessing that PresAl is irritated by that 1 false positive and will now quickly sample as many people as quickly as possible to improve the already impressive sensitivity figure. Negative samples will be much easier to obtain. Meanwhile they’ll tidy the remaining paperwork and be ready to formalise everything within weeks.
I can’t see this being ignored by any govt. It’s a vast improvement on the competition. As noted, yesterday was a bit of a kicking on the markets in general so we held up well and should start seeing the lack of technical risk being fully unwound. It’s all about product launch and orders from here. For starters, our covfefe fwiends are still twiddling their thumbs waiting.
RE: Outstanding result - SIMPLY THE BEST THERE IS20 Apr 2021 20:13
It’s insanely good. 100% sensitivity for infectious loads. Much easier to use so it can provide full confidence that you’re not infectious if you test negative. Why wouldn’t every possible place where humans gather want our test to be used?